RESUMEN
Chronic kidney dysfunction is associated with increased mortality in multiple cancer types. Preliminary evidence suggests the same to be true for B-large cell lymphomas (B-LCL). To analyze the relationship of glomerular filtration rate (GFR) and outcome of B-LCL in detail we collected data on outcomes of 285 consecutive patients with newly diagnosed B-LCL treated at our institution with standard rituximab-containing regimens who did not have preexisting kidney disease or urinary tract obstruction at presentation. Median age was 59, range 18 to 87, 145 were male and 140 females. Forty-four had GFRâ <â 60 mL/min, 123 had 60 to 90 mL/min, and 118â >â 90 mL/min. Median follow-up of surviving patients was 49 months and estimated 3-year survival 76%. In univariate analysis age (Pâ <â .001), GFR (Pâ =â .014), stage (Pâ <â .001), performance status (Pâ =â .044), chemotherapy regimen (Pâ <â .01), and international prognostic index (IPI) (Pâ <â .001) were statistically significant prognostic factors. In multivariate analysis, age and GFR remained the only independent prognostic factors. Subtracting 1 from the IPI score of patients who had GFRâ >â 90 mL/min and IPIâ >â 1 resulted in a prognostic index that divides patients into 3 prognostic groups (low riskâ =â 0-1, intermediate riskâ =â 2-3 and high riskâ =â 4-5) with an acceptable patient distribution frequency (38%, 39%, and 23%, respectively) and improved statistical significance and separation in comparison to IPI (5-year survival rates of 92%, 74%, and 42%, respectively). GFR is an important independent prognostic factor for B-LCL that should be taken into account in clinical decision making and data analysis and probably be incorporated in prognostic indices.